surmount-1 trial tirzepatide non-diabetic obesity weight loss after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 Gastrointestinal tolerability and weight reduction

As a long acting GLP-1 RA, semaglutide can translocate to the brain stem, lateral septum (LS), and hypothalamus, interact directly with various GLP-1 receptor subtypes and modulate the activity of neural pathways involved in food intake, reward, and energy expenditure (19, 20)

You cant be like, "I want to eat and exercise in such a way that I only lose fat." It just doesnt do that. Interestingly, there is currently a weight loss drug bimagrumab which going through trials for retention of muscle mass

Overview of microRNA biogenesis, mechanisms of actions, and circulation

CT-868 is an injectable GLP-1/GIP dual agonist in development as an adjunct therapy to insulin for T1D

For women whose weight has been driven partly by that pull, this effect can matter as much as the metabolic one